Drug Search Results
More Filters [+]

Nifuroxazide

Alternative Names: nifuroxazide, nifuroxazida
Latest Update: 2024-05-14
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Bosnia | Bulgaria | Chile | Colombia | Croatia | Czech | Dominican Republic | Ecuador | Egypt | France | Greece | Hong Kong | Indonesia | Italy | Jordan | Korea | Lebanon | Mexico | Morocco | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Serbia | Singapore | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Cairo University
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nifuroxazide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Brain Diseases|Hepatic Encephalopathy|Colitis, Ulcerative

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT05988528

P3

Recruiting

Colitis, Ulcerative

2027-08-20

CL (3202)

P3

Recruiting

Hepatic Encephalopathy|Brain Diseases

2024-12-01

Recent News Events